Leads Biolabs Doses First Patient in LBL-047 Lupus Trial
Leads Biolabs announced the first patient has been dosed in the Phase I Part B trial of LBL-047 for systemic lupus erythematosus.
Leads Biolabs announced the first patient has been dosed in the Phase I Part B trial of LBL-047 for systemic lupus erythematosus.